| Dr Fred P Rosenfelt, MD | |
|
120 S Spalding Dr Ste 401, Beverly Hills, CA 90212-1842 | |
| (310) 205-0771 | |
| Not Available |
| Full Name | Dr Fred P Rosenfelt |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 49 Years |
| Location | 120 S Spalding Dr Ste 401, Beverly Hills, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306842802 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | G32656 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cedars-sinai Medical Center | Los angeles, CA | Hospital |
| Ronald Reagan Ucla Medical Center | Los angeles, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Regents Of The University Of California | 1355248584 | 1177 |
News Archive
As a part of its ongoing commitment to interoperability standards, Merge Healthcare, a leading health IT solutions provider, announced that it successfully passed interoperability tests at the Integrating the Healthcare Enterprise (IHE), North American Connectathon event in Chicago, Illinois. During the testing, which connects vendor solutions to promote better electronic information exchange, Merge demonstrated interoperability with every vendor pairing, which included some of the largest companies in the world.
A deadly coronavirus pandemic, economic instability and civil unrest menace the mental well-being of millions.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.
An analysis of survey data from more than 280,000 young adults ages 18-35 showed that cannabis (marijuana) use was associated with increased risks of thoughts of suicide (suicidal ideation), suicide plan, and suicide attempt.
Peptide: N-glycanase (NGLY1) is an evolutionarily conserved enzyme for removing N-linked glycans (N-glycans) from glycoproteins and is involved in proteostasis of N-glycoproteins in the cytosol. In 2012, a rare genetic disorder called NGLY1 deficiency was discovered by an exome analysis.
› Verified 2 days ago
| Entity Name | The Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235107566 PECOS PAC ID: 1355248584 Enrollment ID: O20031223000439 |
News Archive
As a part of its ongoing commitment to interoperability standards, Merge Healthcare, a leading health IT solutions provider, announced that it successfully passed interoperability tests at the Integrating the Healthcare Enterprise (IHE), North American Connectathon event in Chicago, Illinois. During the testing, which connects vendor solutions to promote better electronic information exchange, Merge demonstrated interoperability with every vendor pairing, which included some of the largest companies in the world.
A deadly coronavirus pandemic, economic instability and civil unrest menace the mental well-being of millions.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.
An analysis of survey data from more than 280,000 young adults ages 18-35 showed that cannabis (marijuana) use was associated with increased risks of thoughts of suicide (suicidal ideation), suicide plan, and suicide attempt.
Peptide: N-glycanase (NGLY1) is an evolutionarily conserved enzyme for removing N-linked glycans (N-glycans) from glycoproteins and is involved in proteostasis of N-glycoproteins in the cytosol. In 2012, a rare genetic disorder called NGLY1 deficiency was discovered by an exome analysis.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Fred P Rosenfelt, MD 5767 W Century Blvd Ste 400, Los Angeles, CA 90045-5631 Ph: () - | Dr Fred P Rosenfelt, MD 120 S Spalding Dr Ste 401, Beverly Hills, CA 90212-1842 Ph: (310) 205-0771 |
News Archive
As a part of its ongoing commitment to interoperability standards, Merge Healthcare, a leading health IT solutions provider, announced that it successfully passed interoperability tests at the Integrating the Healthcare Enterprise (IHE), North American Connectathon event in Chicago, Illinois. During the testing, which connects vendor solutions to promote better electronic information exchange, Merge demonstrated interoperability with every vendor pairing, which included some of the largest companies in the world.
A deadly coronavirus pandemic, economic instability and civil unrest menace the mental well-being of millions.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.
An analysis of survey data from more than 280,000 young adults ages 18-35 showed that cannabis (marijuana) use was associated with increased risks of thoughts of suicide (suicidal ideation), suicide plan, and suicide attempt.
Peptide: N-glycanase (NGLY1) is an evolutionarily conserved enzyme for removing N-linked glycans (N-glycans) from glycoproteins and is involved in proteostasis of N-glycoproteins in the cytosol. In 2012, a rare genetic disorder called NGLY1 deficiency was discovered by an exome analysis.
› Verified 2 days ago
Igor Gorokhov, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9400 Brighton Way, Suite 410, Beverly Hills, CA 90210 Phone: 310-256-2426 Fax: 310-954-9373 | |
Miss Pritha Payel Gupta, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 8641 Wilshire Blvd Ste 115, Beverly Hills, CA 90211 Phone: 310-855-7002 Fax: 310-855-7003 | |
Daniel Benhuri, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 9400 Brighton Way, Beverly Hills, CA 90210 Phone: 310-683-0180 | |
Dr. Seymour Levine, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 150 North Robertson Blvd, #350, Beverly Hills, CA 90211 Phone: 310-687-2855 Fax: 310-687-7433 | |
Dr. Reed Scott Wilson, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 435 N Roxbury Dr, Suite #300, Beverly Hills, CA 90210 Phone: 310-859-9170 | |
Dr. Alex Foxman, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 8920 Wilshire Blvd Ste 310, Beverly Hills, CA 90211 Phone: 310-274-0657 Fax: 310-274-6083 | |
Dr. Raymond Zimmer, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 8501 Wilshire #150, Beverly Hills, CA 90211 Phone: 310-358-3496 Fax: 310-247-9614 |